A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-29. Anything still debated is marked as such rather than presented as settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
The Mazda Familia (Japanese: マツダ ファミリア, Matsuda Famiria), also marketed prominently as the Mazda 323, Mazda Protegé and Mazda Allegro, is a small family car that was manufactured by Mazda between 1963 and 2003. The Familia line was replaced by the Mazda3/Axela for 2004. It was marketed as the Familia in Japan, which means "family" in Latin. For export, earlier models were sold with nameplates including: "800", "1000", "1200", and "1300". In North America, the 1200 was replaced by the Mazda GLC, with newer models becoming "323" and "Protegé". In Europe, all Familias sold after 1977 were called "323". The Familia was also rebranded as the Ford Laser and Ford Meteor in Asia, Oceania, Southern Africa, some Latin American countries and, from 1991, as the Ford Escort and Mercury Tracer in North America. In addition, the Familia name was used as the Mazda Familia Wagon/Van, a badge-engineered version of the Nissan AD wagon (1994–2017) and Toyota Probox (2018–present). Mazda Familias were manufactured in the Hiroshima Plant and also assembled from "knock-down kits" in various countries including Taiwan, Indonesia, Malaysia, South Africa, Zimbabwe, Colombia, and New Zealand. Some of these plants kept manufacturing the Familia long after it was discontinued at home.
The two substrates of this enzyme are L-lysine and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (2S)-2,3,4,5-tetrahydropyridine-2-carboxylic acid (1), ammonia, reduced NADH, and a proton. The enzyme is highly specific for L-lysine as substrate, although S-(2-aminoethyl)-L-cysteine can act as a substrate, but more slowly.
=== Nuclear spins and magnets === All nucleons, that is neutrons and protons, composing any atomic nucleus, have the intrinsic quantum property of spin, an intrinsic angular momentum analogous to the classical angular momentum of a spinning sphere. The overall spin of the nucleus is determined by the spin quantum number S. If the numbers of both the protons and neutrons in a given nuclide are even then the system prefers to minimize its spin, giving S = 0, i.e. there is no overall spin. Then, just as electrons pair up in nondegenerate atomic orbitals, so do even numbers of protons or even numbers of neutrons (both of which are also spin-1/2 particles and hence fermions), giving zero overall spin. However, an unpaired proton and unpaired neutron will have a lower energy when their spins are parallel, not anti-parallel. This parallel spin alignment of distinguishable particles does not violate the Pauli exclusion principle. The lowering of energy for parallel spins has to do with the quark structure of these two nucleons. As a result, the spin ground state for the deuteron (the nucleus of deuterium, the 2H isotope of hydrogen), which has only a proton and a neutron, corresponds to a spin value of 1, not of zero. On the other hand, because of the Pauli exclusion principle, the tritium isotope of hydrogen must have a pair of anti-parallel spin neutrons (of total spin zero for the neutron spin-pair), plus a proton of spin 1/2. Therefore, the tritium total nuclear spin value is again 1/2, just like the simpler, abundant hydrogen isotope, 1H nucleus (the proton).
Sources: en.wikipedia.org
=== Preferred habitat === Bowfin prefer vegetated sloughs, lowland rivers and lakes, swamps, and backwater areas, and are occasionally found in brackish water. They are well camouflaged and difficult to spot in slow water with abundant vegetation. They often seek shelter under roots and submerged logs. Oxygen-poor environments can be tolerated because of their ability to breathe air.
=== Innovations === The initial stages of the Industrial Revolution had much to do with larger military forces—it became easy to mass-produce weapons and thus to equip larger forces. Britain was the largest single manufacturer of armaments in this period. It supplied most of the weapons used by the coalition powers throughout the conflicts. France produced the second-largest total of armaments, equipping its own huge forces as well as those of the Confederation of the Rhine and other allies. Napoleon showed innovative tendencies in his use of mobility to offset numerical disadvantages, as demonstrated in the rout of the Austro–Russian forces in 1805 in the Battle of Austerlitz. The French Army redefined the role of artillery, forming independent, mobile units, as opposed to the previous tradition of attaching artillery pieces in support of troops. The semaphore system had allowed the French War-Minister, Carnot, to communicate with French forces on the frontiers throughout the 1790s. The French continued to use this system throughout the Napoleonic wars. Aerial surveillance was used for the first time when the French used a hot-air balloon to survey coalition positions before the Battle of Fleurus, on 26 June 1794.
=== Oxidative half === In the oxidative half of the mechanism, Cys63 nucleophilically attacks the nearest sulfide unit in the GSSG molecule (promoted by His467), which creates a mixed disulfide bond (GS-Cys58) and a GS− anion. His467 of GSR then protonates the GS- anion to release the first molecule of GSH. Next, Cys63 nucleophilically attacks the sulfide of Cys58, releasing a GS− anion, which, in turn, picks up a solvent proton and is released from the enzyme, thereby creating the second GSH. So, for every GSSG and NADPH, two reduced GSH molecules are gained, which can again act as antioxidants scavenging reactive oxygen species in the cell.
== As a drug target == With its integral role in HIV replication, HIV protease has been a prime target for drug therapy. HIV protease inhibitors work by specifically binding to the active site by mimicking the tetrahedral intermediate of its substrate and essentially becoming “stuck,” in the catalytic cycle, disabling the enzyme. After assembly and budding, viral particles lacking active protease cannot mature into infectious virions. Several protease inhibitors have been licensed for HIV therapy. There are ten HIV-1 PR inhibitors that are currently approved by the Food and Drug Administration: indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, amprenavir, fosamprenevir, atazanavir, tipranavir, and darunavir. Many of the inhibitors have different molecular components and thus different mechanistic actions, such as blocking the active site. Their functional roles also extend to influencing circulation concentrations of other inhibitor drugs (ritonavir) and being used only for certain circumstances in which the virus exhibits tolerance of other inhibitors (tipranavir).
Sources: en.wikipedia.org
== Related enzymes == Prophenoloxidase is a modified form of the complement response found in some invertebrates, including insects, crabs and worms. Hemocyanin is homologous to the phenol oxidases (e.g. tyrosinase) since both enzymes sharing type copper active site coordination. Hemocyanin also exhibits PPO activity, but with slowed kinetics from greater steric bulk at the active site. Partial denaturation actually improves hemocyanin's PPO activity by providing greater access to the active site. Aureusidin synthase is homologous to plant polyphenol oxidase, but contains certain significant modifications. Aurone synthase catalyzes the formation of aurones. Aurone synthase purified from Coreopsis grandiflora shows weak tyrosinase activity against isoliquiritigenin, but the enzyme does not react with the classic tyrosinase substrates l-tyrosine and tyramine and must therefore be classified as catechol oxidase. Laccase, a multi-copper oxidase, is often considered a subclass of polyphenol oxidase. Laccase and polyphenol oxidase differ in the type of substrates that they catalyse. Catachol oxidase (a type of polyphenol oxidase) catalyses the oxidation of ortho-diphenols to ortho-quinones. Tyrosinase (another type of polyphenol oxidase), catalyses both the oxidation of monophenols to ortho-diphenols, and the subsequent oxidation of ortho-diphenols to ortho-quinones. Laccase, in contrast, catalyses the oxidation of para-diphenols to para-quinones.
== Function == mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12–rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.
The working group defined four criteria that must be fulfilled: "like-mindedness", "significant player", "mutual benefit" and "global considerations." The working group's recommendations were presented at the OECD Ministerial Council Meeting on 13 May 2004, and on 16 May 2007, the OECD Ministerial Council decided to open accession discussions with Chile, Estonia, Israel, Russia, and Slovenia, and to strengthen cooperation with Brazil, China, India, Indonesia, and South Africa through a process of enhanced engagement. Chile, Slovenia, Israel, and Estonia all became members in 2010. In March 2014, the OECD halted membership talks with Russia in response to its annexation of Crimea. In 2013, the OECD decided to open membership talks with Colombia and Latvia. In 2015, the Organisation opened talks with Costa Rica and Lithuania. Latvia became a member on 1 July 2016, and Lithuania soon followed on 5 July 2018. Colombia signed the accession agreement on 30 May 2018 and became a member on 28 April 2020. On 15 May 2020, the OECD decided to extend a formal invitation for Costa Rica to join the OECD, which joined as a member on 25 May 2021. Other countries that have expressed interest in OECD membership are Argentina, Brazil, Croatia, Malaysia and Peru. In January 2022, the OECD reported that membership talks were underway with Argentina, Brazil, Bulgaria, Croatia, Peru and Romania. In March 2022, the OECD suspended the participation of Russia and Belarus due to the ongoing Russian invasion of Ukraine.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.